Last checked at 9 Jul 2021 14:29
9 July 2021
Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Director/PDMR Shareholding
The Company was notified that on 7 July 2021 Adam Power, Group Development Director, transferred 3,437,500 of shares in Surgical Innovations (the "Ordinary Shares") from the Power Discretionary Trust into his own name at a price of 3.25 pence per Ordinary Share.
Following this transaction, the Power Discretionary Trust does not hold any Ordinary Shares and there is no change to the combined beneficial holding of Adam Power in the Company which remains at 31,562,500 Ordinary Shares, representing approximately 3.39% of the issued share capital of the Company.
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | |
David Marsh, CEO | Tel: 0113 230 7597 | |
Charmaine Day, Co Sec & GFC | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | |
Aubrey Powell / Rachel Hayes/ Iqra Amin | ||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name | Adam Power | |||
2 | Reason for the notification | ||||
a) | Position/status | Group Development Director | |||
b) | Initial notification/ Amendment | Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Surgical Innovations Group plc | |||
b) | LEI | 2138004GHGUH3HUZE156 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1p
GB0004016704 | |||
b) | Nature of the transactions | Transfer of Ordinary Shares | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
3.25 pence per share | 3,437,500 | ||||
d) | Aggregated information - Aggregated volume - Price |
n/a- single transaction | |||
e) | Date of the transaction | 7 July 2021
| |||
f) | Place of the transaction | Off-market Transaction
| |||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses and products are available on the following websites:
www sigroupplc com
www surginno com
www elementalhealthcare co.uk
To receive regular updates by email, please contact si@walbrookpr.com.